Project 2: Novel NeurosERMs and NeurosARMs for Protection Against Alzheimer Pathology Roberta Diaz Brinton, PhD, PI and Christian J. Pike, PhD, PI Our goal is to develop safe and efficacious alternative hormone therapies to prevent or delay late-onset age-associated Alzheimer's disease (AD). This proposal builds on our extensive knowledge of the mechanisms of estrogen and androgen action in brain and the extensive epidemiological data indicating that estrogen-based hormone therapy reduces the risk of developing AD and the emerging findings that androgen therapy can sustain cognitive function during aging. Basic science analyses of gonadal hormone action in neurons provide a mechanistic understanding for the healthy cell bias of hormone action. Studies proposed herein are a preclinical plan to translate our basic understanding of gonadal hormone mechanisms in brain into rationally designed molecules that will function as brain selective estrogen receptor modulators (NeurosERMs) and androgen receptor modulators (NeurosARMs). The proposed translational analyses build on several decades of basic science discovery that have established the solid foundation of predictive gonadal hormone outcomes in brain. It is on this foundation that we propose to develop innovative, safe and efficacious alternatives to hormone therapy to sustain neurological health and to prevent the dysfunction and pathology of late-onset age-associated AD.
Specific Aim I proposes in vitro screens of NeurosERM and NeurosARM candidate molecules for efficacy to induce markers of neuroprotection, neural defense, neural plasticity. Further, we will assess the ability of candidate NeurosERMs and NeurosARMs to reduce B-amyloid accumulation and tau hyperphosphorylation. Consistent with the mission of the USC ADRC, we will also evaluate indicators of vascular viability and integrity to access efficacy of NeurosERMs / sARMs to prevent vascular disease. Molecules that reach criterion for in vitro efficacy will move to in vivo testing in Aim II.
In Specific Aim II, we will evaluate efficacies of NeurosERM and NeurosARM candidate molecules in a transgenic mouse model of AD to 1) reduce levels of tau phosphorylation and B-amyloid accumulation;2) prevent cognitive deficits;3) protect against vascular injury;and 4) prevent proliferation in reproductive tissues.

Public Health Relevance

Abundant research at multiple levels indicates that estrogen- and androgen-based therapies in aging women and men, respectively, have therapeutic efficacy in reducing risk of Alzheimer and vascular diseases. This project will identify novel mimetics of estrogen (NeurosERMs) and androgens (NeurosARMs) for translational purposes that will protect the brain and vasculature but lack deleterious effects of reproductive tissues.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005142-29
Application #
8450815
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4)
Project Start
Project End
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
29
Fiscal Year
2013
Total Cost
$199,475
Indirect Cost
$78,234
Name
University of Southern California
Department
Type
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Nation, Daniel A (2018) Blood Pressure and Cerebral Blood Flow in Alzheimer Disease. Hypertension 72:68-69
Hadjichrysanthou, Christoforos; McRae-McKee, Kevin; Evans, Stephanie et al. (2018) Potential Factors Associated with Cognitive Improvement of Individuals Diagnosed with Mild Cognitive Impairment or Dementia in Longitudinal Studies. J Alzheimers Dis 66:587-600
Hanfelt, John J; Peng, Limin; Goldstein, Felicia C et al. (2018) Latent classes of mild cognitive impairment are associated with clinical outcomes and neuropathology: Analysis of data from the National Alzheimer's Coordinating Center. Neurobiol Dis 117:62-71
Burke, Shanna L; Hu, Tianyan; Fava, Nicole M et al. (2018) Sex differences in the development of mild cognitive impairment and probable Alzheimer's disease as predicted by hippocampal volume or white matter hyperintensities. J Women Aging :1-25
Wang, Qi; Guo, Lei; Thompson, Paul M et al. (2018) The Added Value of Diffusion-Weighted MRI-Derived Structural Connectome in Evaluating Mild Cognitive Impairment: A Multi-Cohort Validation1. J Alzheimers Dis 64:149-169
Wang, Tingyan; Qiu, Robin G; Yu, Ming (2018) Predictive Modeling of the Progression of Alzheimer's Disease with Recurrent Neural Networks. Sci Rep 8:9161
Agogo, George O; Ramsey, Christine M; Gnjidic, Danijela et al. (2018) Longitudinal associations between different dementia diagnoses and medication use jointly accounting for dropout. Int Psychogeriatr 30:1477-1487
Aydogan, Dogu Baran; Jacobs, Russell; Dulawa, Stephanie et al. (2018) When tractography meets tracer injections: a systematic study of trends and variation sources of diffusion-based connectivity. Brain Struct Funct 223:2841-2858
Gahm, Jin Kyu; Shi, Yonggang; Alzheimer’s Disease Neuroimaging Initiative (2018) Riemannian metric optimization on surfaces (RMOS) for intrinsic brain mapping in the Laplace-Beltrami embedding space. Med Image Anal 46:189-201
Emrani, Sheina; Libon, David J; Lamar, Melissa et al. (2018) Assessing Working Memory in Mild Cognitive Impairment with Serial Order Recall. J Alzheimers Dis 61:917-928

Showing the most recent 10 out of 590 publications